Free Trial
→ Elon's new 'super startup' (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:LNAI

Lunai Bioworks 11/14/2025 Earnings Report

Lunai Bioworks logo
$0.26 -0.02 (-7.01%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$0.25 0.00 (-1.24%)
As of 05/15/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Lunai Bioworks EPS Results

Actual EPS
$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lunai Bioworks Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lunai Bioworks Announcement Details

Quarter
Date
11/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lunai Bioworks Earnings Headlines

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock
May 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dickinson-wright-and-fox-rothschild-join-forces-to-file-lawsuit-against-john-doe-naked-short-sellers-of-lunai-common-stock-1036140517
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292467/0/en/dickinson-wright-and-fox-rothschild-join-forces-to-file-lawsuit-against-john-doe-naked-short-sellers-of-lunai-common-stock.html
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified a new venture quietly incubating inside Tesla. It has nothing to do with EVs, AI, or robotics, yet it generated $12 billion in 2025 alone. Blackstone calls the broader opportunity a $23 trillion investment runway. Adam believes investors who position themselves before July 22 are early. He's also giving away a free ticker pick in his latest briefing.tc pixel
 |  Banyan Hill Publishing (Ad)
Financial Comparison: Lunai Bioworks (NASDAQ:LNAI) & Merck KGaA (OTCMKTS:MKGAF)
May 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759317
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
May 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lunai-bioworks-completes-20-million-preferred-issuance-to-acquire-cns-delivery-and-neurotherapeutic-ip-302761369.html
Lunai Bioworks Inc.: Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
April 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68206868-lunai-bioworks-inc-lunai-bioworks-nasdaq-lnai-and-geneial-sign-loi-to-build-rare-disease-patient-cohorts-for-pharma-partnerships-008.htm
See More Lunai Bioworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lunai Bioworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lunai Bioworks and other key companies, straight to your email.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

View Lunai Bioworks Profile
Earnings Tools